TY - JOUR
T1 - The CBI-R detects early behavioural impairment in genetic frontotemporal dementia
AU - Genetic FTD Initiative (GENFI)
AU - Nelson, Annabel
AU - Russell, Lucy L.
AU - Peakman, Georgia
AU - Convery, Rhian S.
AU - Bouzigues, Arabella
AU - Greaves, Caroline V.
AU - Bocchetta, Martina
AU - Cash, David M.
AU - van Swieten, John C.
AU - Jiskoot, Lize
AU - Moreno, Fermin
AU - Sanchez-Valle, Raquel
AU - Laforce, Robert
AU - Graff, Caroline
AU - Masellis, Mario
AU - Tartaglia, Maria Carmela
AU - Rowe, James B.
AU - Borroni, Barbara
AU - Finger, Elizabeth
AU - Synofzik, Matthis
AU - Galimberti, Daniela
AU - Vandenberghe, Rik
AU - de Mendonça, Alexandre
AU - Butler, Chris R.
AU - Gerhard, Alexander
AU - Ducharme, Simon
AU - Le Ber, Isabelle
AU - Santana, Isabel
AU - Pasquier, Florence
AU - Levin, Johannes
AU - Otto, Markus
AU - Sorbi, Sandro
AU - Rohrer, Jonathan D.
AU - Afonso, Sónia
AU - Almeida, Maria Rosario
AU - Anderl-Straub, Sarah
AU - Andersson, Christin
AU - Antonell, Anna
AU - Archetti, Silvana
AU - Arighi, Andrea
AU - Balasa, Mircea
AU - Barandiaran, Myriam
AU - Bargalló, Nuria
AU - Bartha, Robart
AU - Bender, Benjamin
AU - Benussi, Alberto
AU - Bertoux, Maxime
AU - Bertrand, Anne
AU - Bessi, Valentina
AU - Maruta, Carolina
N1 - Funding Information:
The Dementia Research Centre is supported by Alzheimer’s Research UK, Alzheimer’s Society, Brain Research UK and The Wolfson Foundation. This work was supported by the NIHR UCL/H Biomedical Research Centre, the Leonard Wolfson Experimental Neurology Centre (LWENC) Clinical Research Facility and the UK Dementia Research Institute, which receives its funding from UK DRI Ltd, funded by the UK Medical Research Council, Alzheimer’s Society and Alzheimer’s Research UK. JDR is supported by an MRC Clinician Scientist Fellowship (MR/M008525/1) and has received funding from the NIHR Rare Disease Translational Research Collaboration (BRC149/NS/MH). This work was also supported by the MRC UK GENFI grant (MR/M023664/1), the Bluefield Project and the JPND GENFI‐PROX grant (2019‐02248). MB is supported by a Fellowship award from the Alzheimer’s Society, UK (AS‐JF‐19a‐004‐517). MB’s work is also supported by the UK Dementia Research Institute which receives its funding from DRI Ltd, funded by the UK Medical Research Council, Alzheimer’s Society and Alzheimer’s Research UK. RSC is supported by a Frontotemporal Dementia Research Studentships in Memory of David Blechner funded through The National Brain Appeal (RCN 290173). Several authors of this publication are members of the European Reference Network for Rare Neurological Diseases (Project ID No 739510). Funding Information
Funding Information:
We thank the research participants for their contribution to the study. The Dementia Research Centre is supported by Alzheimer’s Research UK, Alzheimer’s Society, Brain Research UK and The Wolfson Foundation. This work was supported by the NIHR UCL/H Biomedical Research Centre, the Leonard Wolfson Experimental Neurology Centre (LWENC) Clinical Research Facility and the UK Dementia Research Institute, which receives its funding from UK DRI Ltd, funded by the UK Medical Research Council, Alzheimer’s Society and Alzheimer’s Research UK. JDR is supported by an MRC Clinician Scientist Fellowship (MR/M008525/1) and has received funding from the NIHR Rare Disease Translational Research Collaboration (BRC149/NS/MH). This work was also supported by the MRC UK GENFI grant (MR/M023664/1), the Bluefield Project and the JPND GENFI‐PROX grant (2019‐02248). MB is supported by a Fellowship award from the Alzheimer’s Society, UK (AS‐JF‐19a‐004‐517). MB’s work is also supported by the UK Dementia Research Institute which receives its funding from DRI Ltd, funded by the UK Medical Research Council, Alzheimer’s Society and Alzheimer’s Research UK. RC is supported by a Frontotemporal Dementia Research Studentships in Memory of David Blechner funded through The National Brain Appeal (RCN 290173). Several authors of this publication are members of the European Reference Network for Rare Neurological Diseases (Project ID No 739510). Open Access funding enabled and organized by Projekt DEAL.
Publisher Copyright:
© 2022 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
PY - 2022/5/1
Y1 - 2022/5/1
N2 - Introduction: Behavioural dysfunction is a key feature of genetic frontotemporal dementia (FTD) but validated clinical scales measuring behaviour are lacking at present. Methods: We assessed behaviour using the revised version of the Cambridge Behavioural Inventory (CBI-R) in 733 participants from the Genetic FTD Initiative study: 466 mutation carriers (195 C9orf72, 76 MAPT, 195 GRN) and 267 non-mutation carriers (controls). All mutation carriers were stratified according to their global CDR plus NACC FTLD score into three groups: asymptomatic (CDR = 0), prodromal (CDR = 0.5) and symptomatic (CDR = 1+). Mixed-effects models adjusted for age, education, sex and family clustering were used to compare between the groups. Neuroanatomical correlates of the individual domains were assessed within each genetic group. Results: CBI-R total scores were significantly higher in all CDR 1+ mutation carrier groups compared with controls [C9orf72 mean 70.5 (standard deviation 27.8), GRN 56.2 (33.5), MAPT 62.1 (36.9)] as well as their respective CDR 0.5 groups [C9orf72 13.5 (14.4), GRN 13.3 (13.5), MAPT 9.4 (10.4)] and CDR 0 groups [C9orf72 6.0 (7.9), GRN 3.6 (6.0), MAPT 8.5 (13.3)]. The C9orf72 and GRN 0.5 groups scored significantly higher than the controls. The greatest impairment was seen in the Motivation domain for the C9orf72 and GRN symptomatic groups, whilst in the symptomatic MAPTgroup, the highest-scoring domains were Stereotypic and Motor Behaviours and Memory and Orientation. Neural correlates of each CBI-R domain largely overlapped across the different mutation carrier groups. Conclusions: The CBI-R detects early behavioural change in genetic FTD, suggesting that it could be a useful measure within future clinical trials.
AB - Introduction: Behavioural dysfunction is a key feature of genetic frontotemporal dementia (FTD) but validated clinical scales measuring behaviour are lacking at present. Methods: We assessed behaviour using the revised version of the Cambridge Behavioural Inventory (CBI-R) in 733 participants from the Genetic FTD Initiative study: 466 mutation carriers (195 C9orf72, 76 MAPT, 195 GRN) and 267 non-mutation carriers (controls). All mutation carriers were stratified according to their global CDR plus NACC FTLD score into three groups: asymptomatic (CDR = 0), prodromal (CDR = 0.5) and symptomatic (CDR = 1+). Mixed-effects models adjusted for age, education, sex and family clustering were used to compare between the groups. Neuroanatomical correlates of the individual domains were assessed within each genetic group. Results: CBI-R total scores were significantly higher in all CDR 1+ mutation carrier groups compared with controls [C9orf72 mean 70.5 (standard deviation 27.8), GRN 56.2 (33.5), MAPT 62.1 (36.9)] as well as their respective CDR 0.5 groups [C9orf72 13.5 (14.4), GRN 13.3 (13.5), MAPT 9.4 (10.4)] and CDR 0 groups [C9orf72 6.0 (7.9), GRN 3.6 (6.0), MAPT 8.5 (13.3)]. The C9orf72 and GRN 0.5 groups scored significantly higher than the controls. The greatest impairment was seen in the Motivation domain for the C9orf72 and GRN symptomatic groups, whilst in the symptomatic MAPTgroup, the highest-scoring domains were Stereotypic and Motor Behaviours and Memory and Orientation. Neural correlates of each CBI-R domain largely overlapped across the different mutation carrier groups. Conclusions: The CBI-R detects early behavioural change in genetic FTD, suggesting that it could be a useful measure within future clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=85133897437&partnerID=8YFLogxK
U2 - 10.1002/acn3.51544
DO - 10.1002/acn3.51544
M3 - Article
C2 - 35950369
AN - SCOPUS:85133897437
SN - 2328-9503
VL - 9
SP - 644
EP - 658
JO - Annals of Clinical and Translational Neurology
JF - Annals of Clinical and Translational Neurology
IS - 5
ER -